Pharmacokinetics of Imipenem/Cilastatin/Relebactam in Critically Ill Patients Receiving Extracorporeal Membrane Oxygenation (ECMO)
Latest Information Update: 09 Aug 2024
Price :
$35 *
At a glance
- Drugs Cilastatin/imipenem/relebactam (Primary)
- Indications Sepsis
- Focus Pharmacokinetics
- 20 Sep 2023 Status changed from recruiting to completed.
- 14 Mar 2022 Planned End Date changed from 31 Aug 2022 to 30 Nov 2022.
- 14 Mar 2022 Planned primary completion date changed from 31 May 2022 to 31 Oct 2022.